Testing povetacicept for primary membranous nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests an investigational drug called povetacicept for people with primary membranous nephropathy, a kidney disease. Researchers want to see if it is safe and helps reduce protein in the urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of primary membranous nephropathy (a kidney condition) from a past biopsy, or be willing to have a biopsy during screening to confirm it.
- You cannot be allergic to the study drug (povetacicept) or any of its ingredients.
- Other standard medical requirements will be checked by the study team.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called telitacicept in people with primary membranous nephropathy, a kidney condition that causes protein leakage in urine. It aims to see if the drug can reduce protein loss and protect kidney function, potentially slowing the disease's progression.
This trial tests a new antibody drug (obinutuzumab) against a standard treatment (cyclophosphamide plus steroids) for people with a kidney condition called primary membranous nephropathy that causes protein leakage. The goal is to see which treatment better reduces protein loss and protects kidney function.
This study looks at how well a treatment works for people with primary membranous nephropathy (PMN), a kidney condition. It is meant for patients who still have high protein in their urine despite taking standard blood pressure medicines.
This trial tests an investigational drug called budoprutug for people with primary membranous nephropathy, a kidney condition. The goal is to see if the drug can reduce protein in the urine and help protect kidney function.
This study tests a new medicine called JMT601 for people with primary membranous nephropathy (a kidney condition causing protein leakage). The goal is to see if the medicine can reduce protein in the urine while being safe.
This trial tests a new drug called ALXN1920 for adults with primary membranous nephropathy (PMN), a kidney disease where the immune system attacks the kidneys. It is for people at high risk of their disease getting worse, and it compares the new drug added to standard care versus standard care alone.
Hear when a new Primary Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.